Table 1.
Clinical manifestation for each patient at baseline a (n = 40)*
| Patient/age (yr) | Disease duration (mo) | Baseline SLEDAI score | Baseline BILAG score | Total cumulative dose of IS | Clinical outcomes after MSCT | Clinical manifestations |
|---|---|---|---|---|---|---|
| 1/46 |
40 |
17 |
12 |
CYC 0.8 gm/mo × 28 mo |
PCR |
LN, A, C, V, H, ANA+, anti-dsDNA+ |
| 2/37 |
41 |
12 |
12 |
CYC 0.8 gm/mo × 35 mo |
PCR |
A, LN, V, ANA+, anti-dsDNA+, H |
| 3/21 |
50 |
11 |
9 |
MMF 1.5 gm/d × 31 mo |
NR |
V, LN, C, anti-SM+ |
| 4/28 |
98 |
9 |
9 |
CYC 0.8 gm/mo × 10 mo, CYC 0.8 gm/mo combined with MMF 1.0 gm/d × 28 mo (discontinue), LEF 20 mg/d × 31 mo |
MCR |
V, A, alopecia, LN, C, ANA+, anti-dsDNA+ |
| 5/26 |
120 |
12 |
8 |
MMF 2.0 gm/d × 50 mo (discontinue), CYC 0.8 gm/mo × 20 mo |
NR |
V, A, LN, ANA+, anti-dsDNA+ |
| 6/23 |
15 |
14 |
19 |
CYC 0.8 gm/mo × 15 mo, LEF 20 mg/d × 10 mo |
NR |
V, A, F, LN, P, ANA+, anti-dsDNA+ |
| 7/20 |
62 |
12 |
18 |
MMF 1.5 gm/d × 34 mo (discontinued), CYC 0.8 gm/mo × 24 mo |
PCR |
A, F, LN, C, P, ANA+ |
| 8/43 |
26 |
34 |
20 |
CYC 0.8 gm/mo × 10 mo (discontinued), LEF 20 mg/d × 10 mo |
PCR → R |
C, V, LN, A, seizures, ANA+ |
| 9/36 |
97 |
10 |
26 |
CYC 0.8 gm/mo × 29 mo |
MCR → R |
C, V, A, LN, P, ANA+ |
| 10/39 |
60 |
10 |
7 |
CYC 0.8 gm/mo × 25 mo (discontinued), LEF 20 mg/d × 30 mo |
PCR |
LN, A, V, ANA+, anti-SM+ |
| 11/22 |
40 |
8 |
16 |
CYC 0.8 gm/mo × 25 mo |
NR |
LN, C, P, ANA+, anti-dsDNA+ |
| 12/20 |
50 |
14 |
13 |
CYC 0.8 gm/mo × 15 mo (discontinued), VCR 1 mg/week × 4times (discontinued) |
NR |
A, severe thrombocytopenia, V, F, ANA+, anti-dsDNA+, anti-SM+ |
| 13/17 |
75 |
7 |
6 |
MMF 1.5 gm/d × 13 mo (discontinued), LEF 20 mg/d × 30 mo |
NR |
Severe thrombocytopenia, LN, A, ANA+, anti-dsDNA+ |
| 14/21 |
39 |
12 |
11 |
CYC 0.8 gm/mo × 17 mo |
NR |
LN, F, P, A, anti-dsDNA+ |
| 15/36 |
60 |
10 |
7 |
LEF 20 mg/d × 20 mo (discontinued), CYC 0.8 gm/mo × 37 mo |
MCR |
LN, V, P, A, ANA+, anti-SM+ |
| 16/16 |
49 |
11 |
15 |
CYC 0.8 gm/mo × 17 mo (discontinued), LEF 20 mg/d × 20 mo |
NR |
LN, A, V, ANA+ |
| 17/44 |
145 |
4 |
8 |
CYC 0.8 gm/mo × 64 mo |
NR |
LN, A, V, C, ANA+ |
| 18/44 |
85 |
8 |
9 |
CYC 0.8 gm/mo × 40 mo |
PCR |
A, LN, F, ANA+, anti-dsDNA+ |
| 19/29 |
86 |
10 |
5 |
CYC 0.8 gm/mo × 24 mo |
PCR → R |
LN, A, P, F, ANA+, anti-dsDNA+ |
| 20/54 |
264 |
8 |
4 |
CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 12 mo, then MMF 1.0 gm/d × 28 mo |
MCR |
LN, A, V, C, ANA+ |
| 21/36 |
121 |
13 |
13 |
CYC 0.8 gm/mo × 25 mo, LEF 20 mg/d × 40 mo |
PCR → R |
LN, A, V, C |
| 22/40 |
24 |
12 |
8 |
CYC 0.8 gm/mo × 18 mo |
NR |
F, V, LN, C, ANA+ |
| 23/35 |
25 |
14 |
24 |
CYC 0.8 gm/mo × 21 mo |
NR |
F, A, V, LN, P |
| 24/27 |
48 |
12 |
7 |
LEF 20 mg/d × 4 mo (discontinued), CYC 0.8 gm/mo × 40 mo |
MCR |
LN, F, A, P, ANA+, anti-SM+ |
| 25/30 |
102 |
10 |
7 |
MMF 2.0 gm/d × 6 mo, then tapered to 1.5 gm/d × 36 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 59 mo |
PCR |
V, A, LN, ANA+, anti-dsDNA+ |
| 26/31 |
62 |
8 |
3 |
MMF 1.5 gm/d × 8 mo, then tapered to 1.0 gm/d × 50 mo, LEF 20 mg/d × 19 mo |
MCR → R |
LN, V, P, ANA+, anti-dsDNA+ |
| 27/51 |
108 |
13 |
29 |
CYC 0.8 gm/mo × 41 mo, CsA 150 mg/d × 30 mo |
NR |
LN, V, A, C, seizures |
| 28/50 |
110 |
10 |
11 |
LEF 20 mg/d × 39 mo (discontinued), CYC 0.8 gm/mo × 36 mo |
MCR |
A, V, LN, ANA+ |
| 29/45 |
102 |
10 |
9 |
CYC 1.2 gm/mo × 22 mo |
NR |
A, V, LN, ANA+, anti-dsDNA+ |
| 30/33 |
62 |
10 |
9 |
CYC 0.8 gm/mo × 21 mo, LEF 20 mg/d × 12 mo |
MCR |
LN, A, P, C |
| 31/32 |
156 |
14 |
12 |
CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 6 mo, then tapered to 1.0 gm/d × 56 mo |
MCR → R |
LN, A, C, P |
| 32/53 |
146 |
12 |
10 |
CYC 0.8 gm/mo × 24 mo, then tapered to 0.6 gm/mo × 42 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 40 mo |
NR |
LN, A, C, anti-dsDNA+ |
| 33/30 |
157 |
8 |
7 |
CYC 0.8 gm/mo × 16 mo (discontinued) |
NR |
V, LN, A, C, H |
| 34/35 |
123 |
10 |
9 |
CYC 0.8 gm/mo × 18 mo, LEF 20 mg/d × 22 mo |
NR |
LN, A, H, C, ANA+ |
| 35/33 |
216 |
10 |
3 |
CYC 0.8 gm/mo × 26 mo |
PCR |
F, LN, V, C, A |
| 36/39 |
99 |
5 |
7 |
CYC 0.8 gm/mo × 14 mo |
MCR |
LN, C, V, anti-dsDNA+ |
| 37/35 |
109 |
6 |
6 |
LEF 20 mg/d × 34 mo |
PCR → R |
LN, C, H, ANA+ |
| 38/31 |
160 |
9 |
7 |
LEF 20 mg/d × 13 mo (discontinued), CYC 0.8 gm/mo × 35 mo |
MCR |
LN, C, V, A |
| 39/50 |
108 |
10 |
12 |
CYC 0.8 gm/mo × 14 mo |
MCR |
F, LN, A, V, C |
| 40/35 | 96 | 8 | 8 | CYC 0.8 gm/mo × 28 mo (discontinued), LEF 20 mg/d × 7 mo | MCR | LN, V, P, C, ANA+ |
aA, Arthralgia; ANA, Antinuclear antibody; Anti-dsDNA, anti-double-stranded DNA antibody; C, Cytopenia; F, Febrile; H, Hypocomplementemia; IS, Immunosuppressive drug; LN, Lupus nephritis; MCR, Major clinical response; NR, Nonresponse; P, Polyserositis; PCR, Partial clinical response; R, Relapse; V, Vasculitis; VCR, Vincristine. Patients’ clinical manifestations were recorded within 1 week before umbilical cord mesenchymal stem cell transplantation. Total patient population = 40. Patients 1 to 26 were enrolled from the Department of Rheumatology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China. Patients 27 to 32 were enrolled from the Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China. Patients 33 to 37 were enrolled from the Department of Rheumatology, Subei People’s Hospital of Jiangsu Province, Yangzhou, China. Patients 38 to 40 were enrolled from the Department of Rheumatology, Jiangsu Provincial People’s Hospital, Nanjing, China.